IGC Stock Overview
A clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IGC Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$0.91 |
| 52 Week Low | US$0.25 |
| Beta | 1.29 |
| 11 Month Change | -10.08% |
| 3 Month Change | -1.11% |
| 1 Year Change | 11.22% |
| 33 Year Change | -73.82% |
| 5 Year Change | -53.77% |
| Change since IPO | -99.35% |
Recent News & Updates
Shareholder Returns
| IGC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.0% | 1.6% | 2.2% |
| 1Y | 11.2% | 10.0% | 31.7% |
Return vs Industry: IGC exceeded the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: IGC underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| IGC volatility | |
|---|---|
| IGC Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IGC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IGC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 67 | Ram Mukunda | igcpharma.com |
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
IGC Pharma, Inc. Fundamentals Summary
| IGC fundamental statistics | |
|---|---|
| Market cap | US$27.57m |
| Earnings (TTM) | -US$12.57m |
| Revenue (TTM) | US$1.18m |
23.3x
P/S Ratio-2.2x
P/E RatioIs IGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGC income statement (TTM) | |
|---|---|
| Revenue | US$1.18m |
| Cost of Revenue | US$518.00k |
| Gross Profit | US$665.00k |
| Other Expenses | US$13.23m |
| Earnings | -US$12.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 56.21% |
| Net Profit Margin | -1,062.47% |
| Debt/Equity Ratio | 1.8% |
How did IGC perform over the long term?
See historical performance and comparison